Our lab is embedded in the richly collaborative Mt Sinai ecosystem, and works closely with the Human Immune Monitoring Center (HIMC), the Icahn Genomics Institute (IGI), and the Early Phase Trial Unit (EPTU). We leverage these interactions to study primary patient samples from first-in-human and biomarker-focused proof-of-concept studies, as well as larger industry-collaboration clinical trials. Our lab has unprecedented access to fresh biospecimens longitudinally within these 'window-of-opportunity' studies notably spanning liver cancer (HCC), lung cancer (NSCLC), colorectal cancer (CRC), while also being able to tap into large retrospective tissue banks and cohorts via the Biorepository Core (BRC).  Extending beyond cancer immunotherapy, the lab is also leading efforts to study novel immunotherapeutics in tackling age-associated inflammation. We have also developed a robust pipeline for human tissue slice cultures (TSCs) to test in situ efficacy of novel drugs and immunotherapies. Crucially, we can extend our findings in human patient contexts to functional studies in mouse models to maximize impactful research with high translational capacity. 

Some of the notable studies are highlighted below: 

• A Phase 1b/2 Trial of Dupilumab Given in Conjunction with PD-1 or PD-L1 Blockade and Anakinra in the Treatment of Relapsed/refractory Metastatic NSCLC: https://www.clinicaltrials.gov/study/NCT05013450

• A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery: https://clinicaltrials.gov/study/NCT05446129

• Neoadjuvant Nivolumab with CCR2/​5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC): https://clinicaltrials.gov/study/NCT04123379

• Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients: https://www.clinicaltrials.gov/study/NCT03916627

• A Phase 1b/2 trial of Lamivudine in the Treatment of Relapsed/Refractory Solid Tumors Progression on Anti-PD-(L)1 blockade: http://clinicaltrials.gov/study/NCT06494579

• A Phase 1b, Multi-cohort Clinical Trial Assessing Safety and Feasibility of Exercise and Spermidine Administered in Conjunction With Lamivudine (RTi) or Rapamycin (mTORi) to Assess Impact on Dynamic Changes of Inflammation and Aging: https://clinicaltrials.gov/study/NCT07058974

• Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC: https://clinicaltrials.gov/study/NCT06088771